Streptozotocin-induced, diabetic mice (C57BL/6) were preimmunized by injecting 25 low temperature, cultured WistarFurth (WF) 
Introduction
Several years ago, Lacy et al. ( 1-3) demonstrated that it was possible to achieve indefinite survival (> 100 d) of rat islet allografts and concordant islet xenografts (rat to mouse) by low temperature culture of the donor islets, a single injection of antilymphocyte serum (ALS), 1 and implantation of the islets into the liver via the portal vein. Low temperature culture of the donor islets was used to diminish the number of passenger leukocytes that was required to achieve indefinite survival of the islets (4) . Naji and his associates (5) have shown that intrathymic transplants of rat islet allografts and a single injection of rat ALS (RALS) would produce indefinite survival of rat islet allografts and induction of immune unresponsiveness. Recently, we compared the intrathymic, intrahepatic, and kid- 1 . Abbreviations used in this paper: ALS, antilymphocyte serum; KC, kidney capsule; MALS, mouse ALS; MST, mean survival time; RALS, rat ALS; WF, Wistar-Furth. ney capsule (KC) sites for induction ofimmune unresponsiveness to rat islet xenografts in mice using low temperature cultured donor islets and a single injection ofmouse ALS (MALS) and RALS (6) . Immune unresponsiveness was not induced with the KC site, however, both the intrathymic and intrahepatic sites permitted the induction of immune unresponsiveness to the islet xenografts.
Intrahepatic transplants of human islet allografts have produced normoglycemia in immunosuppressed diabetic patients with kidney transplants using partially purified (80-90%) islet preparations (7, 8) . Achievement of indefinite survival and induction of immune unresponsiveness in rodent models have used pure, hand-picked islet preparations, using special procedures to eliminate contaminating lymph nodes, acinar tissue, and ducts from the final preparation. Obviously, hand-picked islets could not be used for human islet allografts since 500,000-800,000 islets are required to achieve normoglycemia. Thus, this study was undertaken to determine whether intrahepatic preimmunization with a small number oflow temperature, cultured rat islets and a single injection ofMALS and RALS into diabetic mice would prevent the rejection of a subsequent transplant ofunaltered islets without additional immunosuppression. If this could be accomplished, then it would raise the possibility of using this approach for human islet allografts since a few thousand pure human islets could be handpicked and used for preimmunization.
Methods
Animals. Male Wistar-Furth (RT1 U) (WF) rats (Harlan Sprague Dawley, Inc., Indianapolis, IN) at 6-8 wk ofage were used as pancreatic islet donors. Male C57BL/6 (H-2b) mice, 6-8 wk of age, were made diabetic by the intravenous injection of streptozotocin ( 167 mg/kg body wt) (Upjohn Co., Kalamazoo, MI) via the tail vein. Only mice with nonfasting plasma glucose concentrations > 400 mg % were used as recipients.
Islet isolation. Pancreatic islets were isolated from the donor rats by the collagenase technique described previously (9, 10) and separated by centrifugation on a Ficoll gradient (11) . Individual islets, free of attached acinar, vascular, and ductal tissue, were selected and removed with a Pasteur pipette with the aid of a dissecting microscope. The selected islets were then examined again under a dissecting microscope using a reflected green light for illumination to permit identification and removal of small lymph nodes that are occasionally present in the preparation (12) . The hand-picked islets were either cultured overnight at 370 before KC transplantation or were cultured in vitro at 24°C for 7 d before intrahepatic preimmunization in a humidified atmosphere of95% air and 5% CO2. The islets were cultured in CMRL-1066 (Gibco Laboratories, Grand Island, NY) tissue culture medium containing 10% FCS, penicillin (100 U/ml), streptomycin sulfate (100 ,gg/ml), D-glucose (1.5 mg/ml), and glutamine (2 mM).
Islet transplantation. Under Nembutal anesthesia (Dodge Laboratories, Fort Dodge, IA), the portal vein technique ( 13) was used for the injection of25 WF islets into the diabetic recipients. The islets had been cultured for 7 
Results
Effect of intrahepatic preimmunization on rat islet xenograft survival. As shown in Table I The remarkable finding was that intrahepatic preimmunization with 25 cultured WF islets and a single injection of MALS and RALS completely prevented rejection of the fresh WF islets transplanted under the KC 3 wk after the preimmunization regimen. All 13 ofthe recipients were still normoglycemic at 60 d after the KC transplant (Table I , group 4). The plasma glucose levels in this group are shown in Fig. 1 . The recipients remained hyperglycemic during the 3-wk interval after preimmunization with the 25 islets and rapidly became normoglycemic when 150 fresh islets were transplanted beneath the KC. At 60 d after transplantation, the kidneys were removed bearing the grafts, and the recipients became hyperglycemic again, indicating that the normoglycemia was being maintained by the KC grafts (Fig. 1) . Histologic examination of the islets in the KC revealed intact islet cells, and the beta cells had a normal degree of beta granulation. Lymphocytes were present around the grafts but not infiltrating them, which is a characteristic finding with established rat islet xenografts in mice ( 1, 2, 6) .
Discussion
This study demonstrates that immune unresponsiveness can be induced within 3 wk after intrahepatic preimmunization Figure 1 . Nonfasting plasma glucose levels (±SEM) in diabetic recipient mice (C57/BL6) after KC transplantation of freshly isolated WF rat islets. The preimmunizing WF rat islets were maintained in vitro at 240C for 7 d before implantation into the liver via the portal vein. All mice received a single injection of MALS (0.2 ml) and RALS (0.2 ml) at the time of implantation. After 60 d of normoglycemia, all mice were nephrectomized (NPX) to document xenograft function. The individual values for days of normoglycemia are shown in Table I. with a small number of cultured rat islets (25) and a single injection of MALS and RALS. Rejection of 150 fresh rat islets transplanted under the KC at 3 wk after preimmunization was prevented in all of the recipients with maintenance of normoglycemia for > 60 d, whereas controls, without preimmunization, had an MST of 16.5±2.5 d. The single injection of MALS and RALS was apparently required since preimmunization with 25 cultured islets alone in the liver produced a slight acceleration of rejection of the subsequent graft of fresh islets under the KC.
The immunologic mechanisms responsible for the induction of immune unresponsiveness in the intrahepatic site are unknown. Posselt et al. (5) have shown that intrathymic transplants ofrat islet allografts with a concurrent, single injection of RALS will produce indefinite survival of the allografts and induction of immune unresponsiveness. They have postulated that ALS depletes peripheral T lymphocytes, prothymocytes now mature in the thymus, and the presence ofdonor alloantigen in the thymus leads to deletion or inactivation of alloreactive clones. We found recently that indefinite survival and induction of concordant islet xenograft immune unresponsiveness could be induced in mice by intrathymic or intrahepatic transplantation of the islets with a single injection of MALS and RALS, whereas the renal subcapsular site would not permit the induction of xenograft immune unresponsiveness (6) . Thus, the microenvironment in the liver appears also to be playing a unique role in the induction ofimmune unresponsiveness to islet xenografts. Previous studies have shown that delivery of antigens to the liver via the portal vein will prevent antibody production ( 15) and intraportal injection of allogeneic spleen cells prolonged the survival of cardiac and parathyroid allografts (16) (17) (18) .
In summary, this study demonstrates that immune unresponsiveness can be achieved across a concordant islet xenograft barrier within 3 wk after intrahepatic preimmunization A108717 and grant ROI DK 01226 from the National Institutes of Health.
